RCM
ALXN

Reynolds Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Reynolds Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,800
Closed -$343K – 167
2015
Q4 		$343K Sell
1,800
-100
-5% -$17.5K 0.37% 83
2015
Q3 		$297K Buy
1,900
+300
+19% +$54.7K 0.37% 97
2015
Q2 		$289K Sell
1,600
-3,500
-69% -$604K 0.28% 137
2015
Q1 		$884K Buy
5,100
+400
+9% +$72.4K 0.77% 22
2014
Q4 		$870K Buy
4,700
+800
+21% +$148K 0.72% 27
2014
Q3 		$647K Buy
3,900
+1,200
+44% +$197K 0.63% 41
2014
Q2 		$422K Buy
2,700
+400
+17% +$63.2K 0.29% 114
2014
Q1 		$350K Buy
2,300
+500
+28% +$79.5K 0.23% 180
2013
Q4 		$239K Sell
1,800
-2,000
-53% -$240K 0.13% 316
2013
Q3 		$441K Buy
3,800
+200
+6% +$21.9K 0.29% 102
2013
Q2 		$333K Buy
+3,600
New +$347K 0.24% 155

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Reynolds Capital Management's ALXN Position: Q1 2016 in Review

Reynolds Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 1,800 shares — an estimated $343K sold.

Reynolds Capital Management first reported a position in ALXN in Q2 2013 and held it in 11 quarters. The position peaked at $884K in Q1 2015. 519 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Reynolds Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Reynolds Capital Management sold 1,800 Alexion Pharmaceuticals shares in Q1 2016, an estimated $343K.
  • Reynolds Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Reynolds Capital Management's Alexion Pharmaceuticals position peaked at $884K in Q1 2015.
  • 519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Reynolds Capital Management's 13F filing for Q1 2016, filed 13 May 2016.